Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Riluzole for the Improvement of Brain-Derived Neuropathic Factor Levels in Cancer Survivors Experiencing Cancer-Related Cognitive Impairment

Trial Status: active

This phase II trial tests how well riluzole works in improving circulating brain-derived neurotrophic factor (BDNF) levels in cancer survivors with cancer related cognitive impairment (CRCI). CRCI encompasses a wide range of symptoms during and after treatment such as memory loss, inability to concentrate, difficulty in thinking, poor response speed and executive functioning. BDNF is a common protein prevalent in blood plasma having proven associations with cognitive impairments. Riluzole is approved for the treatment of a nerve disease called amyotrophic lateral sclerosis. However, its impact on BDNF levels and cognitive function have yet to be explored in cancer patients and survivors. Riluzole may work to improve BDNF levels in cancer survivors with CRCI.